Planet Payment [LSE:AIM: PPT and PPTR; OTCQX: PLPM], a leading international multi-currency payment and data processor, is pleased to announce today the following changes in its senior management.  Robert J. Cox has accepted appointment as Chief Financial Officer and Treasurer and Seth Asofsky, currently the Company’s CFO, will assume the role of Senior Vice President, US Region.

Cox will report to Philip Beck, Chairman and Chief Executive Officer of Planet Payment and will oversee the Company's global accounting and treasury functions, financial planning and analysis. Cox will assume the role at the end of the year. Seth Asofsky, who has held the position of Chief Financial Officer since October 2003, will take over responsibility for United States business and strategy and continues as a member of senior management, also reporting to Mr. Beck.

Cox, 44, most recently served as Executive Vice President, Chief Financial Officer and Treasurer at Harris Interactive, the NASDAQ listed global custom market research firm. "Bob is a seasoned financial executive who brings strong financial, operational, and broad based business skills, as well as corporate transactional experience," said Beck. "With Bob's track record of managing high growth with profitability, I am looking forward to his contributing significantly to the next phase of the Company's global growth."

"This is an exciting time for Planet Payment," said Cox. "Its continuing technological innovation and strong customer pipeline make a very powerful combination for driving the Company towards sustainable profitability. I am very pleased to be joining the Company at this stage in its development."

Prior to working at Harris Interactive, Cox was the Senior Vice President, Chief Financial Officer and Treasurer of DealerTrack Holdings, Inc., a publicly traded provider of on-demand software and data solutions for the automotive retail industry. Cox served in the top finance role at DealerTrack for nearly eight years. During his tenure, revenue at the company grew from $1 million to over $240 million through a combination of organic growth and acquisitions. Prior to DealerTrack Cox held senior financial positions at Triton International Inc., and Green Stamp America Inc. He began his career in the audit practice at KPMG LLP. Cox holds a Master of Business Administration, Finance from Columbia University Graduate School of Business and a Bachelor of Business Administration, Accounting from St. Bonaventure University, and is a New York State Certified Public Accountant.

Seth Asofsky has acted as Planet Payment’s CFO during its critical growth phase and its maturation from a private company start-up to a publicly traded, full service, registered third party processor, now operating in 10 countries around the world.  During his tenure, the Company achieved its first quarters of EBITDA profitability and put itself firmly on the road to positive cashflow.

“Seth’s experience and depth of knowledge of the financial operations of the Company will stand him in good stead in his new role” said Beck.  “The cross-fertilization of skills and knowledge of the Company’s management team across different areas of the business is a key part of our development.”

“The opportunity to take over responsibility for one of our foremost business areas, is tremendously exciting and a challenge I’m looking forward to,” added Asofsky.  “The United States is one of the most important markets for the Company’s solutions and we look forward to achieving the same kind of growth in our US business that we have seen in other regions”

-ends-

Enquiries to:

Planet Payment, Inc.
Philip D. Beck, Chairman & CEO                                              Tel: + 1 516 670 3200
                                                                                                    www.planetpayment.com
Redleaf Communications Ltd  (UK PR for Planet Payment)
Emma Kane / Rebecca Sanders-Hewett /                                planet@redleafpr.com
Henry Columbine                                                                       Tel: +44 20 7566 6700

Canaccord Adams Limited (UK)(Nomad for Planet Payment)
Mark Williams and Andrew Chubb                                             Tel +44 20 7050 6500

Canaccord Adams, Inc. (US) (DAD for Planet Payment)
Andy Viles                                                                                   Tel: +1 617 371 3900

About Planet Payment®

Planet Payment’s Common shares trade in the UK on AIM under the symbols PPT for unrestricted Common shares and PPTR for Reg S Common shares and in

the United States on the OTCQX under the symbol PLPM.

Planet Payment enables processors, acquiring banks and their merchants to accept, process and reconcile credit card transactions in multiple currencies,

allowing cardholders to view prices and settle transactions in their native currency.  The Pay in Your Currency service is a component of Planet Payment’s suite of

multi-currency processing solutions, which include a multi-currency pricing e-commerce service and a Dynamic Currency Conversion service. Planet Payment’s

BuyVoice™, a mobile payment and commerce solution, allows merchants to accept payments and sell product to customers using any mobile or landline phone.

With the iPAY™ gateway, Planet Payment also offers comprehensive Internet processing solutions for credit card and electronic check payments.

Planet Payment is headquartered in New York and has offices in Atlanta, Beijing, Bermuda, Delaware, London, Hong Kong, Shanghai and Singapore.

COMPANY ANNOUNCEMENT:

Results of Annual General Meeting held on 19 November 2009

(ASX: LCT; OTCQX: LVCLY)

ASX Announcement –19 November 2009

The following voting results are in respect of the resolutions laid before Members at the Annual General Meeting of Living Cell Technologies Ltd held today is provided in accordance with Listing Rule 3.13.2 and section 251AA (2) of the Corporations Act.

The Chairman announced that he would vote all undirected proxies in favour of all resolutions.

The total number of proxy votes exercisable by all proxies validly appointed was 56,242,308. 

Resolution 1   Remuneration Report (non binding):

“That the Remuneration Report required by section 300A of the Corporations Act, as contained in the Director's Report of the Company, for the year ended 30 June 2008 be adopted.”

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

Resolution 2   Election of Mr Robert Finder

“That Robert Finder, who was appointed a Director during the year, and who retires in accordance with Clause 9.2 of the Company’s Constitution and, being eligible, offers himself for election, be elected as a Director of the Company. Details of which are set out in the explanatory notes to resolution 2 in the notice of meeting”.

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

Living Cell Technologies Limited

ABN 14 104 028 042

2

Resolution 3   Election of Mr David McAuliffe

“That David McAuliffe, who was appointed a Director during the year, and who retires in accordance with Clause 9.2 of the Company’s Constitution and, being eligible, offers himself for election, be elected as a Director of the Company. Details of which are set out in the explanatory notes to resolution 3 in the notice of meeting”.

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

Resolution 4    Re-election of Professor Robert Elliott

“That Professor Robert Elliott retires by rotation in accordance with Clause 6.1 of the Company’s Constitution and being eligible, offers himself for re-election, details of which are set out in the explanatory notes to resolution 4 in the notice of meeting”.

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

Resolution 5   Re-election of Mr Laurie Hunter

“That Mr Laurie Hunter retires by rotation in accordance with Clause 6.1 of the Company’s Constitution and being eligible, offers himself for re-election, details of which are set out in the explanatory notes to resolution 5 in the notice of meeting”.

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

Living Cell Technologies Limited

ABN 14 104 028 042

3

Resolution 6 Approval of issue of options to Robert Finder or his nominee in accordance with Listing Rule 10.11

“That approval be given pursuant to ASX Listing Rule 10.11 for the issue of 150,000 unlisted options over ordinary shares at a nil issue price and an exercise price of $0.25 per share and 250,000 unlisted options over ordinary shares at a nil issue price and an exercise price of $0.35 per share to Robert Finder or his nominee, details of which are set out in the explanatory notes to resolution 6 in the notice of meeting”.

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

Resolution 7 Approval of issue of options to David McAuliffe or his nominee in accordance with Listing Rule 10.11

“That approval be given pursuant to ASX Listing Rule 10.11 for the issue of 150,000 unlisted options over ordinary shares at a nil issue price and an exercise price of $0.25 per share and 250,000 unlisted options over ordinary shares at a nil issue price and an exercise price of $0.35 per share to David McAuliffe or his nominee, details of which are set out in the explanatory notes to resolution 7 in the notice of meeting”.

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

Resolution 8 Approval of issue of options to David Brookes or his nominee in accordance with Listing Rule 10.11

“That approval be given pursuant to ASX Listing Rule 10.11 for the issue of 250,000 unlisted options over ordinary shares at a nil issue price and an exercise price of $0.25 per share and 250,000 unlisted options over ordinary shares at a nil issue price and an exercise price of $0.35 per share to David Brookes or his nominee, details of which are set out in the explanatory notes to resolution 8 in the notice of meeting”.

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

Living Cell Technologies Limited

ABN 14 104 028 042

4

Resolution 9 Approval of Directors Deed of Access, Insurance and Indemnity

“That for the purposes of section 195(4) of the Corporations Act 2001 and all other purposes:

1.         approval is given to the Company to enter into a Director’s Deed of Access, Insurance and Indemnity between the Company and each of the current Directors of the Company, in substantially the same form as that which is submitted to the 2009 Annual General Meeting, and signed by the Chairman for identification, and to the Company providing benefits in accordance with the Deeds to each of the current Directors; and

2.         any Director and the Secretary of the Company be authorised to sign, seal and deliver on behalf of the Company, each such Director’s Deed of Access, Insurance and Indemnity. Details of which are set out in the explanatory notes to resolution 9 in the notice of meeting”.

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

By order of the board

Nick Geddes

Company Secretary

-Ends-

For further information: www.lctglobal.com

About Living Cell Technologies: www.lctglobal.com

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases.  The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders.  For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels.  The Company entered clinical trials for its diabetes product in 2007.  For the treatment of Parkinson’s disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain.  LCT’s technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection.  LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT’s business, which can be  identified by the use of forward-looking terminology such as “promising,” “plans,” “anticipated,” “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to,” “potential,” “seeking to,” “goal,” “could provide,” “intends,” “is being developed,” “could be,” “on track,” or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Corporate Highlights

Operations

* Drilled and completed three new wells at Mtsare Khevi Field. 

* Preparations underway to install gas sales related infrastructure at Mtsare Khevi Field.

* Currently drilling one new well at Mirzaani Field with logging operations underway.

* Recently passed one million hours worked without injury milestone, following more than 600 consecutive days of safe operations.

Financial

* Raised approximately $7.6 million through equity placement in September. Proceeds are   funding continued investment at the Mirzaani and Mtsare Khevi fields within the Shallow Fields Production Unit.

* Results for the three months ending September 30, 2009 reflect a net loss of $13.4 million, or $0.17 per share on a fully-diluted basis. This loss compares to a net loss of $10.4 million, or $0.14 per share for the corresponding three months of 2008. Increase in net loss due primarily to a $3.4 million non-cash derivative expense associated with the issuance of warrants as part of the September equity placement.

* Received payment of $1.9 million in September for crude oil sales that will be reflected in fourth quarter results.

Operations Update

Shallow Fields Production Unit  

Since September, progress has been made in executing the work programs and gas-sales related infrastructure investments announced in connection with the company’s September equity placement. These activities are aimed at increasing oil and gas production from the Mirzaani and Mtsare Khevi fields, two of four undeveloped fields within the Shallow Fields Production Unit. Frontera believes that successful completion of these work programs will increase Frontera’s total daily production in Georgia to as much as 1,000 barrels of oil equivalent per day (boepd). Current daily production is approximately 250 barrels of oil per day.

At the Mtsare Khevi Field, the next phase of drilling operations began as planned in September and is scheduled to be completed prior to year end. Three of four new planned wells were drilled, completed and placed into production in continuation of the development drilling campaign that commenced in August 2008. The fourth well is expected to be completed in December, which would bring the total wells drilled in the program to 18. Ongoing work is designed to develop both oil and gas reservoirs associated with the Akchagil formation, situated between 200 meters and 350 meters in depth.

Oil production operations are currently focused on maintaining and increasing current daily production rates. To mitigate anticipated natural well decline rates and enhance the low recovery characteristics of the Akchagil’s oil bearing reservoirs, investments are also underway to implement pump optimization programs, waterflood and frac-stimulation initiatives prior to year end. Current daily oil production is approximately 100 barrels per day from eight of the wells drilled to date and these production engineering initiatives are expected to help maintain and increase production from month to month.

The remaining nine wells are classified as gas wells, and efforts to commence gas production and associated sales from these wells are also underway. Current plans call for installation of new infrastructure for the transportation of as much as 100,000 cubic meters of gas per day (589 boepd) to a pipeline within twelve kilometers of the field. This work is expected to be completed early in the first quarter of 2010.

At the Mirzaani Field during the month of October, the Mirzaani #1 well commenced drilling in the underdeveloped southeastern portion of the field and reached a planned total depth of approximately 1,500 meters during the second week of November. While drilling, the well encountered multiple known field reservoir horizons associated with the Lower Pliocene age Shiraki formation between 1,000 meters and 1,500 meters, as well as multiple associated oil shows. An eighteen meter core sample was taken in one of these reservoir horizons in order to provide a fresh understanding of the field’s reservoirs. Open-hole logging operations are currently underway, and once associated analysis is complete, the well is expected to be completed and tested in approximately two weeks.

Frontera’s next well at the Mirzaani Field, the Mirzaani #5, is planned to commence in early December at a location situated in an undeveloped area of the field known as Mirzaani Field Northwest. The well is expected to reach a total depth of 1,250 meters by the end of December and is located 600 meters northwest of the Mirzaani #2 discovery well that Frontera drilled earlier this year. The new #5 well is planned to appraise the recent field extension discovery.

While technical complications associated with cementing and completion of the Mirzaani #2 well have prevented sustained production from being achieved, the data obtained from the well established the presence of potentially significant undeveloped oil reserves in both the previously undeveloped Mirzaani Field Northwest area and in the Mirzaani Field proper. This data provided the technical basis for drilling both the #1 and #5 wells.

Based on analysis of programs to date at both fields, Frontera estimates the two fields contain over 50 million barrels of prospective resources within the Shallow Fields Production Unit. New reserve reports are expected to be completed following the current work programs.

Frontera's Shallow Fields Production Unit is located in the central portion of Block 12 and represents what the company believes to be an extensive trend of low-cost, low-risk undeveloped oil and gas reserves. Containing four discovered yet undeveloped or underdeveloped fields that have additional exploration potential, objectives are considered to be traditional, well-known reservoirs of Pliocene and Miocene age that are situated at depths from 10 meters to 1,500 meters.

Third Quarter 2009 Financial Results

For the three months ending September 30, 2009, the company incurred a net loss of $13.4 million, or $0.17 per share on a fully-diluted basis. This loss compares to a net loss of $10.4 million, or $0.14 per share for the corresponding three months of 2008. The increase in net loss is due primarily to a $3.4 million non-cash derivative expense associated with the issuance of warrants as part of the company’s $7.6 million equity placement in September.

There were no crude oil sales completed during the three months ended September 30, 2009. However, an advance payment of $1.9 million was received in the quarter for a crude oil sale of approximately 38,000 barrels in October, out of a total $2.4 million proceeds for such sale. There were no crude oil sales during the corresponding quarter in 2008.

Total operating costs and expenses decreased to $6.7 million for the three months ended September 30, 2009 compared to $7.7 million for the same period in 2008. Field operating and project costs decreased $0.6 million to $0.7 million during the three months ended September 30, 2009 as compared to $1.3 million for the three months ended September 30, 2008. Substantially all of the decrease was attributable to a decrease in expatriate and national staff in the 2009 period.

General and administrative expenses decreased $0.8 million to $5.4 million for the three months ended September 30, 2009 from $6.2 million for the comparable period in 2008. The decrease was generally attributable to a series of cost cutting measures instituted in the first quarter of 2009, primarily related to headcount reductions in Georgia and Houston. Implementation of cost reduction initiatives are ongoing in order to continue to bring down costs in line with the current focus on the Shallow Fields Production Unit.

Total other expense increased to $6.8 million in the three month period ended September 30, 2009 from $2.7 million in the three month period ended September 30, 2008. The $4.1 million increase is primarily attributable to an increase in interest expense of $0.1 million, an increase in derivative expense of $3.4 million, a $0.2 million decrease in interest income and a $0.4 million loss on sale of investments.
 
Steve C. Nicandros, Chairman and Chief Executive Officer, commented:

“I am pleased and encouraged with the continued progress of operations at our Shallow Fields Production Unit and I look forward to the results from our current work program. Together with implementation of plans to continue to reduce costs through the end of this year, we remain very focused on achieving increased cash flow generation from operations as we move into 2010.

In addition, as we continue to build a strong foundation for our company by focusing our near-term efforts on increasing cost-effective production from our Shallow Fields Production Unit, we are pursuing strategies designed to continue near-term investment at the Taribani Field Unit and the Basin Edge Play Unit. In this context, during the third quarter, we also commenced analysis of possible options related to restructuring our long-term debt that are designed to enhance Frontera’s ability to continue to pursue realization of the significant value that our historical investments have highlighted within our portfolio.”

Enquiries:

Frontera Resources Corporation
Liz Williamson
Vice President, Investor Relations and Corporate Communications
(713) 585-3216
lwilliamson@fronteraresources.com

Nominated Adviser and Broker:

Canaccord Adams
Jeffrey Auld/Ryan Gaffney/Elijah Colby
+44 20 7050 6500

Notes to editors:

1. Frontera Resources Corporation is an independent Houston, Texas, U.S.A.-based international oil and gas exploration and production company whose strategy is to identify opportunities and operate in emerging markets around the world. Frontera has operated in Georgia since 1997 where it holds a 100 percent working interest in a production sharing agreement with the government of Georgia. This gives Frontera the exclusive right to explore for, develop and produce oil and gas from a 5,060 square kilometer area in eastern Georgia known as Block 12. Frontera Resources Corporation shares are traded on the London Stock Exchange, AIM Market - Symbol: FRR and via the Over-the-Counter Market, U.S.A. – OTCQX Symbol: FRTE. For more information, please visit www.fronteraresources.com. For more information regarding Frontera’s work at the Shallow Fields Production Unit, please visit: www.fronteraresources.com/Operations.php?link_id=43.

2. Information on Reserve Estimates: The prospective resources estimates contained in this announcement were determined in accordance with the petroleum resource definitions adopted by the Society of Petroleum Engineers (SPE), World Petroleum Council (WPC) and the American Association of Petroleum Geologists (AAPG) in 2000. Prospective resources are those quantities of petroleum which are estimated, on a given date, to be potentially recoverable from undiscovered accumulations. Gerard Bono, Frontera's Vice President and Chief Reservoir Engineer, who is a member of the SPE, is the qualified person who reviewed and approved the statements in this announcement and the prospective resources estimates associated with the Mirzaani Field and Mtsare Khevi Field. These estimates are being reviewed by Netherland, Sewell & Associates and will be released as soon as practicable.

3. This release may contain certain forward-looking statements, including, without limitation, expectations, beliefs, plans and objectives regarding the potential transactions, potential debt restructuring, potential drilling schedule, well results and other matters discussed in this release, as well as reserves, future drilling, development and production. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: future exploration and development activities; availability and performance of needed equipment and personnel; the company’s ability to raise capital to fund the planned exploration and development programs; seismic data; evaluation of logs, cores and other data from wells drilled; fluctuations in oil and gas prices; weather conditions; general economic conditions; the political situation in Georgia and relations with neighboring countries; and other factors listed in Frontera's financial reports, which are available at www.fronteraresources.com/Investors.php?link_id=23. There is no assurance that Frontera's expectations will be realized, or that any potential transactions will be completed, and actual results may differ materially from those expressed in the forward-looking statements.

(ASX: LCT; OTCQX: LVCLY)

Chairman’s (Dr David Brookes) Address to the 2009 LCT AGM 18^th November - Sydney

Welcome to the 2009 Annual General Meeting, my first as Chairman.

LCT continues to evolve on many levels and progress towards commercialisation, with the highlight being the recent commencement of our world leading New Zealand trial of DIABECELL®.

Developing non-drug based replacement therapies for chronic medical conditions remains the philosophical goal. These treatments have the potential to improve and simplify patient outcomes and, in doing so, reward investors.

It is pleasing to note that International sentiment is changing towards xenotransplantation as an exciting and viable treatment option. This is clearly delineated in a report by the World Health Organisation (Changsa Communiqué Nov2008) which recognises the potential for xenotransplantation to treat a wide range of serious diseases, such as diabetes and kidney disorders. LCT finds itself as a leader in the areas of diabetes and cell encapsulation, and on behalf of the shareholders, I would like to take the opportunity to thank Prof. Elliott, Dr.Tan, their committed team and all the employees of LCT.

It has been a year of change at Board level. Very sadly   Mr.David Collinson, a co-founder of LCT, lost his battle with cancer –his tenacity and passion for LCT were well recognised and appreciated. The stability, loyalty, and achievements of the LCT staff remain as a testament to his contribution.

I would like to take this opportunity to formally welcome the two new members to the LCT Board, Mr. Bob Finder and Mr. David McAuliffe. Both bring a great depth of commercial biotechnology experience to the company. Also I take this opportunity to thank Mr. Simon O’Loughlin for his work as Chairman, and for remaining   on the Board.

The Russian trial has significantly advanced our DIABECELL® project by delivering critical data on safety and clinical benefit.  On behalf of LCT, I would like to extend a formal thank you to the Russian patients for their contribution. LCT looks forward to remaining in contact with all the patients in the longer term. Similarly, the involvement of the NZ patients is appreciated. I expect the NZ trial to reflect the benefits experienced by the Russian participants and to have even more positive outcomes based on the higher dosing.

LCT has also been successful in raising funds, in what had been a difficult financial market environment. We raised $4.2million in July and we currently have a Share Purchase Plan underway. The combined proceeds of these capital raisings improve our financial foundations and allow us to enter 2010 with stability and a clear focus to accelerate DIABECELL®.

Finally, I would like to thank our many supporters. The process of developing a safe, sustainable medical product takes time and patience. The way forward for DIABECELL®has been delineated by the trial process. The New Zealand Government has been and remains a long term supporter.   Our shareholders have been tested by the tribulations of biotechnology and difficult world markets but are in sight of their loyalty being rewarded.

Thank you.

For further information, including the annual report, you are invited to visit the company’s website   http://www.lctglobal.com/    where you may also register to receive email updates on the company.

About Living Cell Technologies: www.lctglobal.com

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases.  The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders.  For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels.  The Company entered clinical trials for its diabetes product in 2007.  For the treatment of Parkinson’s disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain.  LCT’s technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection.  LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT’s business, which can be  identified by the use of forward-looking terminology such as “promising,” “plans,” “anticipated,” “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to,” “potential,” “seeking to,” “goal,” “could provide,” “intends,” “is being developed,” “could be,” “on track,” or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

U.S. SECURITIES AND EXCHANGE COMMISSION

Litigation Release No. 21305 / November 18, 2009

Securities and Exchange Commission v. Big Apple Consulting USA, Inc., MJMM Investments, LLC, Marc Jablon, Matthew Maguire, Mark C. Kaley, and Keith Jablon, Civ. Action No. 09-cv-1963 (M.D. Fla.) (JA)

SEC Charges Investor Relations Firm and its Executives with Fraud, Registration Violations, and Acting as an Unregistered Broker-Dealer

Today the Securities and Exchange Commission ("Commission") filed a civil action in the U.S. District Court for the Middle District of Florida, alleging that investor relations firm Big Apple Consulting USA, Inc. ("Big Apple"), its wholly-owned subsidiary MJMM Investments, LLC ("MJMM"), and four of its executives-CEO Marc Jablon, vice president Matthew Maguire, MJMM president Mark Kaley, and Keith Jablon, vice president of another Big Apple subsidiary-made public misrepresentations and material omissions about the financial state of CyberKey Solutions, Inc., ("CyberKey") while the two entities sold hundreds of millions of CyberKey shares. These CyberKey shares were sold under no registration statement and no legitimate exemption from registration. The SEC also charged Big Apple and MJMM with acting as unregistered broker-dealers, and Marc Jablon, Maguire, and Kaley with aiding and abetting the two entities' violations in that respect.

According to the SEC's complaint, the Big Apple executives learned by August 8, 2006, that CyberKey's only significant source of revenue, a supposed $25 million purchase order from the U.S. Department of Homeland Security ("DHS"), could not be located by DHS itself and almost certainly did not exist. Despite this knowledge, the Big Apple team continued to promote CyberKey and its business relationship with DHS and sold hundreds of millions of CyberKey shares into the public market. In addition to planning and editing press releases, Big Apple used a telephone calling room of 14 to 50 callers to promote CyberKey stock, including the company's relationship with DHS, to registered brokers. In doing so, Big Apple and MJMM acted as dealers in connection with the distribution of CyberKey stock and as brokers by participating in securities transactions at key points in the chain of distribution of CyberKey shares.

The SEC's complaint charges each of the defendants with violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder, as well as with violations of Section 17(a) of the Securities Act of 1933 ("Securities Act"). The SEC's complaint also charges Big Apple, MJMM, Maguire and Marc Jablon with violating Sections 5(a) and 5(c) of the Securities Act. Finally, the complaint charges Big Apple and MJMM with violations of Section 15(a) of the Exchange Act and Marc Jablon, Maguire and Kaley with aiding and abetting the entities' violations of Section 15(a).

The SEC's complaint requests permanent injunctions, disgorgement of ill-gotten gains plus prejudgment interest, and civil penalties against all of the defendants. The complaint also seeks penny stock bars against Big Apple, MJMM, Maguire, and Marc Jablon.

 SEC Complaint

http://www.sec.gov/litigation/litreleases/2009/lr21305.htm